Severe sepsis in Poland - Results of internet surveillance of 1043 cases

Medical Science Monitor

Volumn 10, Issue 11, 2004, Pages

  Kübler, Andrzej ^a   Durek, Grazyna ^a   Zamirowska, Agnieszka ^a   Duszyńska, Wiesława ^a   Pałysińska, Barbara ^b   Gaszyński, Wojciech ^c   Pluta, Andrzej ^d  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Silesian Hospital   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d District Hospital No 3   (Poland)

Author keywords

Infection; Intensive care unit; Organ dysfunction; Severe sepsis

Indexed keywords

ACTIVATED PROTEIN C; AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; FLUCONAZOLE; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; AGE; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; DISEASE COURSE; FEMALE; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH SURVEY; HUMAN; INTENSIVE CARE UNIT; INTERNET; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLAND; PROGNOSIS; SEPSIS; TREATMENT OUTCOME;

FEMALE; HUMANS; INTENSIVE CARE UNITS; INTERNET; MALE; MIDDLE AGED; POLAND; PROGNOSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 9144252142     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bone RC, Balk RA, Cerra FB et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest, 1992; 101: 1644-55
2. Warren BL, Eid A, Singer P et al: High-dose antithrombin 111 in severe sepsis. A randomised, controlled trial. JAMA, 2001; 286: 1869-78
3. Bernard GL, Vincent JL, Laterre PF et al: Eficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 2001; 344: 699-709
4. Angus DC, Linde-Zwirble WT, Lidicker J et al: Epidemiology of severe sepsis in the United States. Analysis of incidence, outcome and associated costs of care. Crit Care Med, 2001; 29: 1303-10
5. The EPISEPSIS Study Group: EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med, 2004; 30: 580-88
6. Padlein A, Goldfrad C, Brady AR et al: Epidemiology of severe sepsis occurring in the first 24h in intensive care units in England. Wales and Northern Ireland. Crit Care Med, 2003; 31: 2332-38
7. van Gestel A, Bakker J, Veraart CPWM, van Hout BA: Prevalence and incidence of severe sepsis in Dutch intensive care units. Critical Care, 2004; 8: R153-R162
8. Flatten H: Epidemiology of sepsis in Norway in 1999. Critical Care, 2004; 8: R180-R184
9. Finfer S, Bellomo R, Lipman J et al: Adult - population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med, 2004; 30: 589-96
10. Silva E, Pedro MA, Sogayar ABC et al: Brazilian sepsis epidemiological study [BASESstudy] Critical Care, 2004: 8: R251-R260
11. Slade E, Tamber PS, Vincent JL: The Surviving Sepsis Campaign: raising awareness to reduce mortality. Critical Care, 2003; 7: 1-2
12. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Defenitions Conference: Intensive Care Med, 2003; 29: 530-38
13. Siegel JH, Rixen D: Clinical and physiological scoring systems for sepsis and organ dysfunction. In: Deitch EA, Vincent JL,Windsor A. [ed] Sepsis and multiorgan dysfunction. Saunders WB, London, 2002; 167-78
14. Alberti C, Brun-Buisson Ch, Burchardi H et al: Epidemiology of sepsis and infection in ICU patients from an international mulucentre cohort study. Intensive Care Med, 2002; 28: 108-21
15. Wenzel RP, Edmond MB: Severe sepsis - National estimates. Crit Care Med, 2001; 29: 1472-73
16. Abraham E, Reinhart K, Opal S et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. A randomised controlled trial. JAMA, 2003; 290: 238-47
17. Vincent JL, Angus DC, Artigas A et al: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med, 2003; 31: 834-40
18. Dhainaut JF, Laterre PF, Janes JM et al: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med, 2003; 29: 894-903
19. Laterre PF, Bernard GR, Trzaskema B, Sashegyi A: INDEPTH - an integrated data base of severe sepsis patients. Crit Care Med, 2003; 31 (Suppl. to no 12): A116